The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-17
DOI
10.1038/s41379-020-0521-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial
- (2019) Susan J. Robertson et al. JOURNAL OF EVALUATION IN CLINICAL PRACTICE
- Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer
- (2019) Mariana A.G. Lima et al. JOURNAL OF EVALUATION IN CLINICAL PRACTICE
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- (2019) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
- (2019) Amila Orucevic et al. BREAST
- Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information
- (2019) Susan J. Robertson et al. Clinical Breast Cancer
- Pathologist's health care value in the triage of Oncotype DX® testing : A value-based pathology study of tumor biology with outcomes
- (2018) David J. Dabbs et al. HISTOPATHOLOGY
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
- (2018) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Applying new Magee equations for predicting the Oncotype Dx recurrence score
- (2018) Maher Sughayer et al. Breast Cancer
- OUP accepted manuscript
- (2018) AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers
- (2018) Ann E. Walts et al. Breast Journal
- Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors
- (2017) Daniel J Farrugia et al. MODERN PATHOLOGY
- Estimating the OncotypeDX score: validation of an inexpensive estimation tool
- (2016) Anne A. Eaton et al. BREAST CANCER RESEARCH AND TREATMENT
- OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
- (2016) Robert C Stein et al. HEALTH TECHNOLOGY ASSESSMENT
- Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer
- (2016) Hyun-seok Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjust cut-off values of immunohistochemistry models to predict risk of distant recurrence in invasive breast carcinoma patients
- (2016) Yen-Ying Chen et al. Journal of the Chinese Medical Association
- Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
- (2016) John M. S. Bartlett et al. JNCI-Journal of the National Cancer Institute
- Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score
- (2016) Thaer Khoury et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
- (2016) John M. S. Bartlett et al. JNCI-Journal of the National Cancer Institute
- A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay
- (2015) Michele M. Gage et al. Clinical Breast Cancer
- Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score
- (2015) Bradley M Turner et al. MODERN PATHOLOGY
- Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
- (2015) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis
- (2013) Helen Ingoldsby et al. BREAST
- An International Ki67 Reproducibility Study
- (2013) Mei-Yin C. Polley et al. JNCI-Journal of the National Cancer Institute
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
- (2013) Molly E Klein et al. MODERN PATHOLOGY
- Interobserver Agreement Among Pathologists for Semiquantitative Hormone Receptor Scoring in Breast Carcinoma
- (2012) David A. Cohen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Impact of Progesterone Receptor Semiquantitative Immunohistochemical Result on Oncotype DX Recurrence Score
- (2012) Beth Z. Clark et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?
- (2011) K. H. Allison et al. BREAST CANCER RESEARCH AND TREATMENT
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- The Oncotype DX Recurrence Score Is Correlated With a Composite Index Including Routinely Reported Pathobiologic Features
- (2010) Joseph Geradts et al. CANCER INVESTIGATION
- A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer
- (2010) Ping Tang et al. CANCER INVESTIGATION
- Histopathologic variables predict Oncotype DX™ Recurrence Score
- (2008) Melina B Flanagan et al. MODERN PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started